Purpose The aim was to evaluate prognostic value of betablocker (BB) administration in acute coronary syndromes (ACS) patients in the percutaneous coronary intervention (PCI) era.
Introduction
Despite therapeutic advances, acute coronary syndromes (ACS) remain a leading cause of death in Western countries, with a detrimental impact on long-term survival, mainly related to the extent of coronary artery disease, features of coronary plaque and ejection fraction (EF) [1] [2] [3] . Beta-blockers (BBs) represent a cornerstone of pharmacological therapy, offering a reduction in long-term mortality and recurrent acute myocardial infarction (re-AMI) [4] , and are a class I recommendation in American and European guidelines, despite the fact that the optimal duration of BB therapy is not known.
The evidence supporting BBs' clinical benefit is largely derived from studies in AMI patients in the pre-percutaneous coronary intervention (pre-PCI) era, without drugeluting stents and without anti-thrombotic therapy [4] [5] [6] .
In the reperfusion era, only reductions in AMI and angina have been observed, while some trials questioned the benefit of BBs in the acute phase of AMI due to an increase in shock rates [7, 8] , and recent analyses have found that early BBs administration was of no benefit [9] . Actually, in the meta-analysis of Al-Reesi et al. [10] , 6-week mortality was not reduced by use of BBs [odds ratio 0.95; 95% confidence interval (CI) 0.90-1.01]. Furthermore, an observational analysis of the REACH registry in more than 10,000 patients found that BB use was not associated with a lower incidence of cardiovascular events among patients with a prior history of myocardial infarction (MI), with an incidence of cardiovascular death, MI and stroke of 16.9 versus 18.6% after 44 months (p = 0.14) [9] . Finally, adherence to BBs is known to be reduced for these patients, with less than 50% of them being compliant after 1 year [10] .
Consequently, we conducted a propensity-score matched analysis on the BleeMACS registry [11] to determine the impact of BB therapy in the spectrum of ACS treated with PCI.
Methods
The present analysis is a sub-analysis of the BleeMACS (Bleeding complications in a Multicenter registry of patients discharged with diagnosis of Acute Coronary Syndrome) study. BleeMACS is an international multicenter investigator-initiated retrospective registry, without financial support, including 15,401 consecutive patients from 15 tertiary hospitals in Europe, Asia, and North and South America (Germany, Netherlands, Poland, Spain, Italy, Greece, Japan, China, Canada and Brazil). More details are available in previous papers, including the definitions of included variables [11] .
Patient Selection
All consecutive patients discharged alive after admission for ACS, including ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI) and unstable angina (UA) diagnosed according to European Society of Cardiology (ESC) guidelines [2] , and treated with PCI during the index admission between 2003 and 2014 were eligible for inclusion. To be as consistent with everyday clinical practice as possible, no prespecified exclusion criteria were described.
Patients were divided into two cohorts based upon therapy at discharge: -Patients with BB therapy -Patients without BB therapy No data about intravenous BB therapy were recorded.
Features of the Patients
Baseline clinical features including age, burden of cardiovascular risk factors, presence of malignancy, history of previous bleeding, creatinine (mg/dL) and hemoglobin (g/ dL) were recorded.
Femoral or radial access for PCI, number and kind of stent (bare metal stents vs drug-eluting stents vs plain balloon-only angioplasty) and thrombolysis were the procedural features described, along with complete revascularization (defined as PCI performed in all coronary vessels with more than 70% stenosis) and EF at discharge.
Medications at discharge, including aspirin, choice of second antiplatelet drug (aspirin, clopidogrel, prasugrel or ticagrelor), BBs, statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers, were recorded.
Endpoint
All-cause death at 1 year of follow-up was the primary endpoint. Secondary endpoints included in-hospital reinfarction, in-hospital heart failure, in-hospital bleedings and transfusion, 1-year MI and 1-year bleeding and 1-year major adverse cardiac events (MACE) (the composite of 1 year death and MI). One-year bleedings were classified according to Thrombolysis in Myocardial Infarction (TIMI) and Bleeding Academic Research Consortium (BARC) criteria [12, 13] . In-hospital events were defined as those occurring during hospitalization for index PCI.
Statistical Analysis
Continuous variables were expressed as mean ± standard deviation; categorical variables were expressed as number and percentage (%). Correlations between parameters and study groups were tested in cross tabulation tables by means of Pearson Chi squared test or Fisher exact test for categorical variables and by one-way analysis of variance (ANOVA) for continuous variables.
Categorical variables were compared with the Fisher exact test. Parametric distribution of continuous variables was tested graphically and with the Kolmogorov-Smirnov test, and the appropriate analyses were used in accordance with the results. For the propensity score, first logistic regression analysis was done for all baseline features that differed between groups with BB and those without BB at univariate analysis and for those relevant from a clinical point of view. Matching was computed after division into quintiles, using the nearest neighbor method, based on the estimated propensity score [14] . Calibration was tested with the Hosmer-Lemeshow test, and accuracy was
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In-hospital re-AMI In-hospital HF P < 0.05 P < 0.05 Fig. 1 Outcomes after propensity score with matching (top) and with Kaplan-Meier analysis (bottom left: freedom from death; bottom right: freedom from reinfarction). HF heart failure, re-AMI recurrent acute myocardial infarction assessed with area under the curve. Standardized differences were evaluated before and after matching to evaluate performance of the model. Survival analysis was performed with Kaplan-Meier analysis and compared with log rank on patients after propensity score with matching. For all patients, Cox multivariate analysis was performed to identify independent predictors of 1-year all-cause death and MI. All statistical analyses were performed with SPSS 21, and differences were considered significant at a = 0.05.
Results
From the 15,401 patients, 15,210 had data on BB at discharge (98%). In the study population, 12,275 patients were on BBs therapy, while 2935 patients were not. At a first comparison, patients on BBs were significantly older, had a higher prevalence of male sex, carried a lower burden of comorbidities such as diabetes, hypertension, history of cardiovascular disease, and had a higher STEMI-presentation rate compared to patients not on BBs [for further AMI acute myocardial infarction, CABG coronary artery bypass grafting, CHF congestive heart failure, NSTEMI non-ST-elevation myocardial infarction, PCI percutaneous coronary intervention, STEMI ST-elevation myocardial infarction, UA unstable angina Tables 1 and 2) were inserted into the logistic regression model to build the propensity score.
Outcomes Before Propensity Score Matching
At 1-year follow-up, 1-year rates of death were lower for patients discharged with BBs (2.9 vs 7.0%, p \ 0.05), as were the rates of MIs (3.8 vs 4.9%, p \ 0.05) and hospital heart failure (4.1 vs 5.2%, p \ 0.05) (see supplementary  Table 3 and Fig. 1 ). By means of propensity score matching, based on clinical presentation, risk factors and procedural features, we selected patients in the on-BBs therapy group in order to create two comparable groups (n = 2935) (see Fig. 1 and Tables 1 and 2 ).
Outcomes After Propensity Score Matching
The primary endpoint of 1-year death was significantly lower in the group on BB therapy [4.5 vs 7%; confirmed also at Kaplan-Meier analysis (see Fig. 1 ), p log rank \ 0.001]. One-year re-AMI was 4.9% in the off-BBs group and 4.5% in the on-BBs group, reaching statistical significance at Kaplan-Meier analysis (p = 0.007) (see Fig. 1 and supplementary Table 4 in the ESM). These results were confirmed at Cox regression (see Tables 3  and 4) , where BB therapy was protective for 1-year death and MI [hazard ratio (HR) 0.349 (95% CI 0.286-0.426) and HR 0.737 (95% CI 0.582-0.932); all p \ 0.005]. Inhospital bleeding and in-hospital transfusion did not differ (respectively, 6.9% in the off-BBs therapy group and 8.1% in the on-BBs therapy group, p = 0.08, and 4.8% in the off-BBs therapy group vs 3.9% in the on-BBs group, p = 0.11), while in-hospital re-AMI and heart failure were, respectively, 1.4 vs 1.5% (p = 0.82) and 5.2 vs 5.6% (p = 0.51).
Sensitivity Analysis for Clinical Features
After propensity score matching, in patients older than 80 years, 1-year death was 16.1% in the off-BBs group and 7% in the on-BBs group (p = 0.045; confirmed also at Kaplan-Meier analysis, p \ 0.001), and 1-year re-AMI was 7.7% in the off-BBs group and 5.8% in the on-BBs group (p = 0.56) (see Fig. 2 ).
BB prescription at discharge was associated with lower mortality in female patients, with rates of death at followup of 6.2 versus 4.1% (p = 0.04) (see the ESM, supplementary Fig. 2 ).
Sensitivity Analysis According to Clinical Presentation
In STEMI patients, BB prescription at discharge was associated with a more than double lower rate of 1-year death than that for patients not on BBs (8.6 vs 4.1%, p \ 0.001; confirmed also at Kaplan-Meier analysis, p \ 0.001), while in UA/NSTEMI patients, a trend toward lower mortality was observed, although this was not significant (5.7 vs 5.3%, p = 0.87) (see Fig. 3 and supplementary Fig. 3 in the ESM) . BB prescription at discharge in STEMI patients was also associated with a lower incidence of MI on Kaplan-Meier analysis (p \ 0.001), but not when comparing crude rate of events.
Sensitivity Analysis According to Completeness of Revascularization
The association between BB prescription at discharge and lower rates of 1-year death was persistent both for patients treated with complete and non-complete revascularization, being more evident for those discharged with critical stenosis not treated during index hospitalization (respectively, 3.9 vs 6.9% and 6.0 vs 12.5%, p = 0.04 and p = 0.03; confirmed also at Kaplan-Meier analysis, p \ 0.001) (see Fig. 4 and supplementary Fig. 4 in the ESM).
Sensitivity Analysis According to Ejection Fraction
Similarly, discharge prescription of BBs was associated with lower 1-year mortality independent of EF, being more relevant in those discharged with a systolic function less than 40% (6.5 vs 2.3%, p = 0.04, for those with an EF more than 40%, and 17.67 vs 7.0% for those with reduced EF, p \ 0.001; confirmed also at Kaplan-Meier analysis, p \ 0.001) (see 
Discussion
The main finding of this study is that BB therapy is associated with better clinical outcomes even in the PCI era and together with all other medical options including novel antiplatelet drugs. This association with better outcomes persisted in STEMI patients and was numerically greater in patients with incomplete revascularization, independent of EF, while we found no difference in outcomes among NSTEMI patients prescribed versus not prescribed BBs at discharge. The importance of the present study lies in subpopulations of ACS patients, in which evidence is lacking. In ACS patients, there is evidence that BBs reduce mortality, but most of the trials were performed in the 1980s in selected patients. This may limit translation of those benefits for patients treated with PCI or antiaggregants like clopidogrel, prasugrel and ticagrelor, which have shown a reduction in recurrent ischemic events [15] [16] [17] [18] [19] . Moreover, indication for PCI has been nowadays expanded to patients with more comorbidities, like renal . BB beta-blocker, HF heart failure, re-AMI recurrent acute myocardial infarction insufficiency, malignancy or pulmonary disease, potentially limiting the impact of BBs on survival [19, 20] . In our study, we found that BBs' association with better outcome persists in STEMI patients, but not in NSTEMI-ACS. Possible reasons of this difference may be related not particularly to the different pathophysiology (related to an erythrocyte-rich red thrombus in STEMI vs a white, fibrinrich, thrombus in NSTEMI) [21] , but especially to different clinical characteristics [21] . Actually, while data from the GRACE registry has shown the potential benefit on 6-month outcomes of BBs therapy [22] , the long-term prognosis remains mainly driven by burden of comorbidities, potentially offsetting the benefit of BBs.
Better outcomes in patients discharged with a prescription for BBs were apparent in patients older than 80 years. They represent an important number of those admitted for ACS in our registry (about 15%), and their number will increase, but there is uncertainty in the literature about their optimal treatment. The use of BBs in older patients is often limited by a large number of medications already prescribed and by side effects which increase with age, such as symptomatic bradycardia, symptomatic hypotension and orthostatic hypotension [23] . Our registry showed that even at 1-year follow-up, the persistence of the benefit of BB therapy was also seen for these patients.
The better outcomes associated with BB prescription at discharge were observed both for patients discharged with complete and not complete revascularization, but was more evident for the latter population, which is at a higher risk of subsequent events [24] . Actually, the absolute risk reduction was 3% in the first group and more than 6% for those discharged with significant stenosis not treated with PCI. These data represent a step forward when compared to those of Chen et al. [25] , which were derived from the Cooperative Cardiovascular Project, showing the increase of benefit of BB in non-revascularized patients versus those treated with percutaneous or surgical revascularization. Moreover, similarly, the paper of Kernis et al. demonstrated the protective role of BBs in patients discharged with STEMI and multivessel disease [26] . In the present registry, we showed that the use of BBs was associated with a clinical benefit more evident in those patients discharged with stenosis potentially triggering acute ischemic events, due to the limiting effect on adrenergic activation and ischemic cascade.
In-hospital bleeding
In-hospital Transfusion* In-hospital re-AMI In-hospital HF P < 0.05 P < 0.05 Fig. 3 Outcomes after propensity score with matching (top) and with Kaplan-Meier analysis (bottom left: freedom from death; bottom right: freedom from reinfarction) for STEMI patients (1889 BB patients vs 1345 not on BB). BB beta-blocker, HF heart failure, re-AMI recurrent acute myocardial infarction, STEMI ST-elevation myocardial infarction
Similarly, as expected, BBs were associated with a protective effect in patients with reduced EF, but also in those with preserved EF. Some experimental data demonstrated an absence of benefit of BBs on left ventricle remodeling in patients with preserved EF; our results, in accordance with those of Konishi et al. and RaposeirasRoubín et al. [27, 28] , confirmed (with a larger sample size) BBs' protective role.
BB prescription at discharge was associated with a lower incidence of MI on Kaplan-Meier analysis, but not when comparing crude rate of events. As demonstrated in Fig. 1 , BBs' association with improved outcomes was most evident after the first month. This is the period in which platelet aggregation and thrombosis risk are more relevant, and these mechanisms are reduced by platelet antiaggregation rather than BBs [29] [30] [31] . After this period, the role of BBs in reducing MI may become more relevant.
The present paper, which demonstrates the benefit of BBs in a large contemporary cohort of ACS patients treated with PCI, differs from that of Bangalore [9] , which showed in a similar number of patients an absence of benefit in patients with prior MI. This difference may not be related to the shorter follow-up of our cohort, potentially focusing on a more acute phase, because Kaplan-Meier curves did not show any differences in the previously quoted paper even in the short term [9] . Moreover, we showed the consistent association of BBs with better clinical outcome across different ages, for those with complete and noncomplete revascularization and preserved or reduced EF. The present results, finally, were different from those of Motivala et al. [20] , who enrolled, prevalently, patients with stable angina without a history of MI and with preserved EF, and this may explain the lack of benefit of survival.
The present paper has some limitations. First, these data are retrospective, with potential adjudication, attribution bias and residual and unmeasured confounding. Despite this, it is not an institutional database, as are many evaluating the effectiveness of BBs in these patients [9, 20] , but rather it is based and evaluated on medical records from physicians, improving the accuracy of the data. Second, we did not have data on different types of BBs, on possible use of ultra short-acting BBs, and when BB therapy was started or discontinued. Despite this, apart from for patients with
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In-hospital re-AMI In-hospital HF P < 0.05 Fig. 4 Outcomes after propensity score with matching (top) and with Kaplan-Meier analysis (bottom left: freedom from death; bottom right: freedom from reinfarction) for complete revascularization patients (1169 BB patients vs 897 not on BB). BB beta-blocker, HF heart failure, re-AMI recurrent acute myocardial infarction heart failure [32] , guidelines do not recommend a particular drug, while the only randomized trial on this topic, the CAMIS (Carvedilol Acute Myocardial Infarction Study), did not show a difference between carvedilol and atenolol [33] . However, as reported in a recent review, in patients with coronary artery disease, selective BB without intrinsic sympathomimetic activity should be preferred [34] . Moreover, cause of death has not been appraised, although the usefulness of BBs to reduce sudden death and cardiac mortality in patients with reduced EF has been largely demonstrated [28] . Rates of in-hospital cardiogenic shock were not recorded, although BB did not increase the rate of in-hospital heart failure irrespectively of EF at discharge. The present results were not derived from randomized controlled trials, but from observational data based on propensity score, with all potential limitations, despite good accuracy [an area under the curve of 0.78 (0.76-0.81)] and discrimination (not significant HosmerLemeshow test) and with an overall good performance when evaluating standardized differences (see the ESM, supplementary Tables 5 and 6 ). Finally, propensity score adjustment was performed for the overall population and not for subgroup analyses, which were performed only for clinical reasons without inferential aims.
Conclusions
We found that beta-blocker therapy was related to lower 1-year risk of all-cause mortality, independent of complete revascularization, admission diagnosis, age and left ventricular ejection fraction, in patients with acute coronary syndromes, who received treatment with percutaneous coronary intervention. This benefit needs to be confirmed in prospective, randomized controlled trials.
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